#ESMO26
💉 Developmental therapeutics
📌 IBI3001: novel EGFR/B7H3 DAR=4
78.9% =>2L
✔️ ORR 30.2%
✔️ ORR for #EGFRm 31.3$ and 62% for SCLC
☣️ 47.4% >G3, mostly hematologic
@OncoAlert @myESMO @ASCO @_SEOM @UTMDAnderson
👇🏽👇🏽
147 views · 4 likes · 4 reposts · 0 replies
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Oriol Mirallas MD · x.com